SCHEMBL2479880

SCHEMBL2479880

NC(=O)c1cnc(Nc2ccc(N3CCN(C(=O)CCl)CC3)cc2)cc1NCc1cccc([N+](=O)[O-])c1

nearest known ligand 0.50

Predicted protein targets (top 11)

geneUniProtsupporting neighboursconfidence
MET P08581 11/20 0.50
KCNH2 Q12809 7/20 0.50
JAK3 P52333 6/20 0.50
IRAK4 Q9NWZ3 2/20 0.50
JAK2 O60674 2/20 0.50
JAK1 P23458 2/20 0.50
TYK2 P29597 2/20 0.50
CSF1R P07333 1/20 0.46
BTK Q06187 1/20 0.46
STAT6 P42226 2/20 0.45
SYK P43405 1/20 0.45

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL12301633 0.92 JAK3 (0.58) METKCNH2JAK3IRAK4JAK2
SCHEMBL12301646 0.91 MET (0.61) METKCNH2JAK3IRAK4JAK2
SCHEMBL2479176 0.89 JAK3 (0.49) METKCNH2JAK3IRAK4JAK2
SCHEMBL2485095 0.89 MET (0.51) METKCNH2JAK3IRAK4JAK2
SCHEMBL2481043 0.89 MET (0.53) METKCNH2JAK3IRAK4JAK2
SCHEMBL2480622 0.88 STAT6 (0.57) METKCNH2JAK3IRAK4JAK2
SCHEMBL2475816 0.88 JAK3 (0.66) JAK3IRAK4JAK2JAK1TYK2
SCHEMBL2474865 0.88 STAT6 (0.55) METJAK3IRAK4JAK2JAK1
SCHEMBL2480059 0.87 MET (0.50) METKCNH2JAK3IRAK4JAK2
SCHEMBL2479837 0.87 MET (0.50) METKCNH2JAK3IRAK4JAK2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-102227409-B Pyridine-3-carboxyamide derivative KOWA CO 2014-03-26 CN disclosed
US-8575153-B2 Pyridine-3-carboxyamide derivative KOWA COMPANY, LTD. (JP) 2013-11-05 US disclosed
US-8575153-B2 Pyridine-3-carboxyamide derivative KOWA COMPANY, LTD. (JP) 2013-11-05 US disclosed
US-8575153-B2 Pyridine-3-carboxyamide derivative KOWA COMPANY, LTD. (JP) 2013-11-05 US disclosed
EP-2380877-A1 PYRIDINE-3-CARBOXYAMIDE DERIVATIVE Kowa Company, Ltd. (JP) 2011-10-26 EP disclosed
EP-2380877-A1 PYRIDINE-3-CARBOXYAMIDE DERIVATIVE Kowa Company, Ltd. (JP) 2011-10-26 EP disclosed
CN-102227409-A Pyridine-3-carboxyamide derivative KOWA CO 2011-10-26 CN disclosed
US-20110237590-A1 PYRIDINE-3-CARBOXYAMIDE DERIVATIVE KOWA COMPANY, LTD. (JP) 2011-09-29 US disclosed
US-20110237590-A1 PYRIDINE-3-CARBOXYAMIDE DERIVATIVE KOWA COMPANY, LTD. (JP) 2011-09-29 US disclosed
US-20110237590-A1 PYRIDINE-3-CARBOXYAMIDE DERIVATIVE KOWA COMPANY, LTD. (JP) 2011-09-29 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110237590-A1 PYRIDINE-3-CARBOXYAMIDE DERIVATIVE JAK3, JAK1, UACA MET 3041/4885KCNH2 3255/4885JAK3 1/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.